Corbus Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis

View Webcast View Presentation

Overview

Latest Financial Results

Stock Information

Symbol

NASDAQ: CRBP

Price

Loading...

Change

Loading...

MKT Cap

Loading...

Volume

Loading...

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company forcused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.

The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. In November 2016, Corbus reported positive topline data results from a Phase 2 study in diffuse cutaneous systemic sclerosis, showing clear signal of clinical benefit with anabasum. The Company recently completed a Phase 2 study of anabasum for the treatment of cystic fibrosis with topline data expected to be announced by the end of the first quarter of 2017. Additionally, Anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis, with a 12-month open-label extension study in dermatomyositis and another Phase 2 study in systemic lupus erythematosus planned to commence in the second quarter of 2017.

Investor Presentation

Download Presentation